Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AssigneeSuperGen, Inc.
InventorJorge F. DiMartino
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
Claims18
A method for treating a patient having a cancer with a combination therapy, comprising:
- administering to said patient a therapeutically effective amount of a DNA methylation inhibitor that is 5-azacytidine or decitabine at a dose ranging from 1 to 50 mg/M2 per day, in combination with a therapeutically effective amount of a histone deacetylase inhibitor selected from the group consisting of trichostatin A, suberoylanilide hydroxamic acid, oxamflatin, suberic bishydroxamic acid, m-carboxy-cinnamic acid bishydroxamic acid, pyroxamide, trapoxin A, apicidin, depsipeptide, N-(2-aminophenyl)-4-[N-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide, butyric acid, phenylbutyrate and arginine butyrate.
Dependencies are inferred from the claim text.